-
-
-
-
-
-
-
Elicio Therapeutics (ELTX) Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study
-
-
-
-
-
-
-
Elicio Therapeutics (ELTX) Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

